These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27336598)

  • 1. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
    Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
    PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    Yang X; Zhang K; Zhang C; Peng R; Sun C
    BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
    Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
    Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.
    Zhou Q; Li W; Leng B; Zheng W; He Z; Zuo M; Chen A
    PLoS One; 2016; 11(6):e0155495. PubMed ID: 27253331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.
    Raei M; Heydari K; Tabarestani M; Razavi A; Mirshafiei F; Esmaeily F; Taheri M; Hoseini A; Nazari H; Shamshirian D; Alizadeh-Navaei R
    BMC Cancer; 2024 Jul; 24(1):908. PubMed ID: 39069608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
    Kim ST; Lira M; Deng S; Lee S; Park YS; Lim HY; Kang WK; Mao M; Heo JS; Kwon W; Jang KT; Lee J; Park JO
    Oncotarget; 2015 Nov; 6(37):40026-35. PubMed ID: 26498688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic accuracy of
    Galvano A; Castellana L; Gristina V; La Mantia M; Insalaco L; Barraco N; Perez A; Cutaia S; Calò V; Bazan Russo TD; Francini E; Incorvaia L; Mirisola MG; Vieni S; Rolfo C; Bazan V; Russo A
    Ther Adv Med Oncol; 2022; 14():17588359221110162. PubMed ID: 36188485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
    Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
    Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
    Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
    Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
    Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
    Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis.
    Hou F; Sun XD; Deng ZY
    Medicine (Baltimore); 2023 Feb; 102(7):e32928. PubMed ID: 36800605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
    Ibrahim EM; Kazkaz GA; Al-Mansour MM; Al-Foheidi ME
    Breast Cancer Res Treat; 2015 Aug; 152(3):463-76. PubMed ID: 26105797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
    Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
    Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
    Li B; Pu K; Ge L; Wu X
    Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis.
    Gu Y; Wan C; Qiu J; Cui Y; Jiang T; Zhuang Z
    PLoS One; 2020; 15(2):e0224001. PubMed ID: 32027658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
    Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.